Guggenheim Reiterates Buy Rating and $55 PT on Valeant Pharmaceuticals (VRX) Following 4Q Beat; 'Growth Prospects Underappreciated'
Tweet Send to a Friend
Guggenheim analyst Louise Chen reiterates Buy rating and $55 price target on Valeant Pharmaceuticals (NYSE: VRX), suggesting muted upside in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
